Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Significance: We recently reported that activin type II receptors (ActRIIs) blockade using bimagrumab could positively impact muscle wasting in mice and humans. However, the specific role of each individual ActRII at regulating adult muscle mass had not been clarified. Here, we highlight the importance of concomitant neutralization of both ActRIIs in controlling muscle mass. Through comparison with single specificity antibodies, we uncover unique features related to bimagrumab and its neutralizing interactions with both ActRIIA and ActRIIB at the structural and cellular levels and in vivo in adult mice. The need for simultaneous engagement and neutralization of both ActRIIs to generate a strong skeletal muscle response confers unique therapeutic potential to bimagrumab, in the context of muscle wasting conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“blocking these receptors can result in profound muscle growth in animals and humans18–22”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, no changes were observed in fiber type composition of muscle treated with BYM338, indicating that hypertrophy occurred regardless of fiber type [37].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Double muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940
Induction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., Miller, C., Regalado, S. G., Loffredo, F. S., Pancoast, J. R., et al. (2014) · Science · doi:10.1126/science.1251152 · Cited by 824
Rebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J., & Attisano, L. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7230-7242.2003 · Cited by 565
Signaling pathways controlling skeletal muscle mass
Egerman, M. A., & Glass, D. J. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.857291 · Cited by 555
Self-citationGDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527 · cited 1×
“The best characterized ligands are myostatin [also known as growth and differentiation factor 8 (GDF8)] (7–9) and activin A (10–13), while there is some uncertainty with regard to the contribution of GDF11 (13–15) at regulating muscle mass and function, although it has been demonstrated that administration of GDF11 in…”
BackgroundSelf-citationInhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
BMP signaling controls muscle mass
Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., Stantzou, A., Mouisel, E., Toniolo, L., Ferry, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2772 · Cited by 467
Bodine, S. C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.011 · Cited by 389
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
Becker, C., Lord, S. R., Studenski, S. A., Warden, S. J., Fielding, R. A., Recknor, C. P., Hochberg, M. C., Ferrari, S. L., Blain, H., Binder, E. F., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00298-3 · Cited by 381
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 2×
“Both agents also prevented muscle wasting in several disease models, ranging from glucocorticoid-induced atrophy (28) to cancer cachexia (26, 29), as indeed myostatin and activin A had been reported to induce muscle wasting and cachexia (5, 6, 30).”
BackgroundLach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 5×
“Both agents also prevented muscle wasting in several disease models, ranging from glucocorticoid-induced atrophy (28) to cancer cachexia (26, 29), as indeed myostatin and activin A had been reported to induce muscle wasting and cachexia (5, 6, 30).”
BackgroundResultInfluentialSelf-citationRegulation of Muscle Mass by Follistatin and Activins
Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., & Barton, E. R. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0127 · Cited by 273
Greenwald, J., Groppe, J., Gray, P., Wiater, E., Kwiatkowski, W., Vale, W., & Choe, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00094-7 · Cited by 263
Structure of the ternary signaling complex of a TGF-β superfamily member
Allendorph, G. P., Vale, W. W., & Choe, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602558103 · Cited by 246
Rooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244
Self-citationMyostatin propeptide‐mediated amelioration of dystrophic pathophysiology
Bogdanovich, S., Perkins, K. J., Krag, T. O. B., Whittemore, L.-A., & Khurana, T. S. (2005) · The FASEB Journal · doi:10.1096/fj.04-2796com · Cited by 242
Campbell, C., McMillan, H. J., Mah, J. K., Tarnopolsky, M., Selby, K., McClure, T., Wilson, D. M., Sherman, M. L., Escolar, D., & Attie, K. M. (2017) · Muscle & Nerve · doi:10.1002/mus.25268 · Cited by 240
The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
Winbanks, C. E., Chen, J. L., Qian, H., Liu, Y., Bernardo, B. C., Beyer, C., Watt, K. I., Thomson, R. E., Connor, T., Turner, B. J., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211134 · Cited by 225 · cited 2×
“A strong interplay between inhibition of the muscle growth repressing Smad2/3 pathway and the converse activation of the growth promoting BMP/Smad1/5 axis has been identified (19, 43, 44).”
BackgroundMorley, J. E. (2012) · Family Practice · doi:10.1093/fampra/cmr063 · Cited by 218
Thompson, T. B. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg156 · Cited by 210
Treatment of sporadic inclusion body myositis with bimagrumab
Amato, A. A., Sivakumar, K., Goyal, N., David, W. S., Salajegheh, M., Praestgaard, J., Lach-Trifilieff, E., Trendelenburg, A.-U., Laurent, D., Glass, D. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001070 · Cited by 210 · cited 1×
“Evidence reported in elderly humans treated with anti-myostatin neutralizing antibody demonstrates a smaller magnitude of muscle mass changes, such as an appendicular lean body mass (aLBM) increase of 2–3% (23, 45), while studies conducted in sporadic inclusion body myositis and sarcopenia patients with bimagrumab dem…”
ResultSelf-citationQuantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease
Schafer, M. J., Atkinson, E. J., Vanderboom, P. M., Kotajarvi, B., White, T. A., Moore, M. M., Bruce, C. J., Greason, K. L., Suri, R. M., Khosla, S., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.023 · Cited by 206
Activin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185 · cited 2×
“Recent work examining the relative contribution of various ligands, activin A, activin B, beyond myostatin, unveiled a strong synergistic response upon blockade of both activin and myostatin (18, 19), with some cross-species difference between mice and primates (18).”
BackgroundMethodA single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 176
Redundancy of myostatin and growth/differentiation factor 11 function
McPherron, A. C., Huynh, T. V., & Lee, S.-J. (2009) · BMC Developmental Biology · doi:10.1186/1471-213x-9-24 · Cited by 165
Weber, D., Kotzsch, A., Nickel, J., Harth, S., Seher, A., Mueller, U., Sebald, W., & Mueller, T. D. (2007) · BMC Structural Biology · doi:10.1186/1472-6807-7-6 · Cited by 147
Choe, S., Greenwald, J., Fischer, W. H., & Vale, W. (1999) · Nature Structural Biology · doi:10.1038/4887 · Cited by 147
A Flexible Activin Explains the Membrane-Dependent Cooperative Assembly of TGF-β Family Receptors
Greenwald, J., Vega, M., Allendorph, G. P., Fischer, W. H., Vale, W., & Choe, S. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.011 · Cited by 144
Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., et al. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0060-8 · Cited by 143
Souza, T. A., Chen, X., Guo, Y., Sava, P., Zhang, J., Hill, J. J., Yaworsky, P. J., & Qiu, Y. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0290 · Cited by 142
Recent advances in the biology and therapy of muscle wasting
Glass, D., & Roubenoff, R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05809.x · Cited by 128
Self-citationChen, J. L., Walton, K. L., Hagg, A., Colgan, T. D., Johnson, K., Qian, H., Gregorevic, P., & Harrison, C. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620013114 · Cited by 116 · cited 2×
“Recent work examining the relative contribution of various ligands, activin A, activin B, beyond myostatin, unveiled a strong synergistic response upon blockade of both activin and myostatin (18, 19), with some cross-species difference between mice and primates (18).”
BackgroundStructural basis for potency differences between GDF8 and GDF11
Walker, R. G., Czepnik, M., Goebel, E. J., McCoy, J. C., Vujic, A., Cho, M., Oh, J., Aykul, S., Walton, K. L., Schang, G., et al. (2017) · BMC Biology · doi:10.1186/s12915-017-0350-1 · Cited by 111
TAK-1/p38/nNFκB signaling inhibits myoblast differentiation by increasing levels of Activin A
Trendelenburg, A., Meyer, A., Jacobi, C., Feige, J. N., & Glass, D. J. (2012) · Skeletal Muscle · doi:10.1186/2044-5040-2-3 · Cited by 104
Self-citationBimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
Hatakeyama, S., Summermatter, S., Jourdain, M., Melly, S., Minetti, G. C., & Lach-Trifilieff, E. (2016) · Skeletal Muscle · doi:10.1186/s13395-016-0098-2 · Cited by 81
Self-citationWOODHOUSE, L., GANDHI, R., WARDEN, S. J., POIRAUDEAU, S., MYERS, S. L., BENSON, C. T., HU, L., AHMAD, Q. I., LINNEMEIER, P., GOMEZ, E. V., et al. (2016) · The Journal of Frailty & Aging · doi:10.14283/jfa.2016.81 · Cited by 80
Lack of evidence for GDF 11 as a rejuvenator of aged skeletal muscle satellite cells
Hinken, A. C., Powers, J. M., Luo, G., Holt, J. A., Billin, A. N., & Russell, A. J. (2016) · Aging Cell · doi:10.1111/acel.12475 · Cited by 71
Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition
Goncalves, M. D., Pistilli, E. E., Balduzzi, A., Birnbaum, M. J., Lachey, J., Khurana, T. S., & Ahima, R. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012707 · Cited by 69
Regulation and actions of activin A and follistatin in myocardial ischaemia–reperfusion injury
Chen, Y., Rothnie, C. L., Spring, D. J., Verrier, E. D., Venardos, K. M., Kaye, D. M., Phillips, D. J., Hedger, M. P., & Smith, J. A. (2014) · Cytokine · doi:10.1016/j.cyto.2014.06.017 · Cited by 33
Mulivor, A. W., Sako, D., Cannell, M., Wallner, S., Hevron, K., Steeves, R. M., Castonguay, R., Pearsall, R. S., & Kumar, R. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.06.281 · Cited by 3
Cited by
Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake
Merz, K. E., & Thurmond, D. C. (2020) · Comprehensive Physiology · doi:10.1002/cphy.c190029 · Cited by 494
Role of Myokines in Regulating Skeletal Muscle Mass and Function
Lee, J. H., & Jun, H.-S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00042 · Cited by 432
“Growing evidence indicates that increasing myostatin and its analog activin A contribute to the incidence of muscle atrophy (Morvan et al., 2017).”
BackgroundBone morphogenetic protein receptor signal transduction in human disease
Gomez‐Puerto, M. C., Iyengar, P. V., García de Vinuesa, A., ten Dijke, P., & Sanchez‐Duffhues, G. (2019) · The Journal of Pathology · doi:10.1002/path.5170 · Cited by 235
“Musculoskeletal Sarcopenia, cachexia, Duchenne muscular dystrophy ActRII-Fc, ActRII ab, Follistatin (NCT01519349) Fracture healing OP-1/BMP7(NCT00679328) Osteoarthritis OP-1/BMP7 (NCT01111045) Muscular dystrophy ActRIIA-Fc, ActrRIIB-Fc [58] Fibrodysplasia ossificans progressiva ALK2 LDN-193189, LDN-212854/ALK2 kinase…”
BackgroundMultimodal cell atlas of the ageing human skeletal muscle
Lai, Y., Ramírez-Pardo, I., Isern, J., An, J., Perdiguero, E., Serrano, A. L., Li, J., García-Domínguez, E., Segalés, J., Guo, P., et al. (2024) · Nature · doi:10.1038/s41586-024-07348-6 · Cited by 205
Understanding cachexia in the context of metastatic progression
Biswas, A. K., & Acharyya, S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0251-4 · Cited by 197
Metadata
- Authors
- Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., Koelbing, C., Leber, X., Schilb, A., Witte, F., Lehmann, S., Koch, E., Geisse, S., Glass, D. J., & Lach-Trifilieff, E.
- Affiliations
- MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland;
- Novartis Institutes for BioMedical Research (CH)
- Novartis (Switzerland) (CH)
- MorphoSys (Germany) (DE)
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA 02139
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-11-06
- Volume
- 114
- Issue
- 47
- Pages
- 12448-12453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5703284
- OpenAlex
- W2767554184
- Cited by
- 142
- References
- 46
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 21 · 2020: 27 · 2019: 18 · 2018: 8
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- Paul Scherrer Institut
- Novartis Institutes for BioMedical Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Physical Performance
- Keywords
- activin type II receptor, ActRIIA, ActRIIB, bimagrumab, myostatin, activin A, skeletal muscle hypertrophy, TGF-beta signaling, receptor antagonism, competitive binding, cachexia, muscle atrophy, GDF11
- MeSH terms
- Animals, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Humans, Hypertrophy, Male, Recombinant Proteins, Signal Transduction, Mice, SCID, Rats, Wistar, Crystallography, X-Ray, Muscle, Skeletal, Antibodies, Blocking, Wasting Syndrome, Bone Morphogenetic Proteins, Activins, Activin Receptors, Type II, Mice, Rats, Growth Differentiation Factors, Myostatin, HEK293 Cells, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.